20(S)-Rg3 blocked epithelial-mesenchymal transition through DNMT3A/miR-145/FSCN1 in ovarian cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epithelial-mesenchymal transition (EMT) is a key driver of cancer progression.
• MicroRNA (miR) dysregulation is implicated in cancer development.
• Ovarian cancer remains a significant health challenge with complex progression mechanisms.

Purpose of the Study:

• To investigate the effect of ginsenoside 20(S)-Rg3 on EMT in ovarian cancer.
• To elucidate the molecular mechanism underlying 20(S)-Rg3's action, focusing on miR-145.
• To evaluate the therapeutic potential of 20(S)-Rg3 in ovarian cancer models.

Main Methods:

• Investigated the impact of 20(S)-Rg3 on miR-145 expression and DNA methylation.
• Utilized cell-based assays to assess EMT markers and the role of DNMT3A.
• Validated FSCN1 as a direct target of miR-145.
• Employed nude mouse xenograft models to assess in vivo efficacy.

Main Results:

• Ginsenoside 20(S)-Rg3 significantly increased miR-145 expression by downregulating DNMT3A, reducing promoter hypermethylation.
• Restoration of DNMT3A expression reversed the anti-EMT effects of 20(S)-Rg3.
• miR-145 directly targets FSCN1, suppressing EMT in ovarian cancer cells.
• In vivo studies confirmed miR-145's role in suppressing ovarian cancer progression.

Conclusions:

• Ginsenoside 20(S)-Rg3 effectively inhibits EMT in ovarian cancer by modulating the DNMT3A/miR-145/FSCN1 pathway.
• The findings highlight 20(S)-Rg3 as a promising therapeutic agent for ovarian cancer.
• Targeting this pathway offers a novel strategy for ovarian cancer treatment.